Oct 24 (Reuters) - A newer class of cancer drugs can delay disease progression or extend survival for breast cancer patients, multiple teams of researchers reported at a major European oncology ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer. Adding the drug enzalutamide to standard hormone therapy reduced the risk of ...

Adding the drug enzalutamide to standard hormone therapy reduced the risk of premature death by more than 40% in patients whose prostate cancer had returned, a large international clinical trial has ...

Nomad has launched its latest Apple Watch accessory, the Stratos Band. It combines lightweight and durable titanium with FKM rubber for a breathable, comfortable, and durable watch band, unlike ...

We may earn a commission from links on this page. Deal pricing and availability subject to change after time of publication. Credit: Illustration by Ian Moore and product image courtesy of Amazon. The ...

Oct. 21, 2025 – A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to unprecedented results of a drug treatment trial in men whose ...

Abstract: This brief presents a hybrid boost DC-DC converter for driving piezoelectric actuators that overcomes the frequency limitation of traditional boost converters and the 3-level, ...

Share on Pinterest A new drug combo therapy significantly improved overall survival rates in males with locally advanced prostate cancer. Maskot/Getty Images A drug combination already used in ...

The trial has shown curability of the combination over a five-year period. Image credit: Nemes Laszlo / Shutterstock.com MSD and Eisai’s combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib ...

As per data presented at the European Society for Medical Oncology (ESMO) 2025 Congress, the Phase III ENGOT-ov65/KEYNOTE-B96 study with Keytruda met the primary endpoint of progression-free survival ...

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in China, Akeso and Summit Therapeutics’ ivonescimab has shown it can delay ...